• HiFiBiO, Pharmsynthez and IBCh sign Covid-19 antibody development deal pharmaceutical-technology
    November 25, 2020
    HiFiBiO Therapeutics has entered into a partnership with Pharmsynthez and Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry RAS (IBCh) to develop and commercialise its SARS-CoV-2 neutralising antibody, HFB30132A, for Covid-19 treatment.
PharmaSources Customer Service